Navigation Links
VARI study could improve treatments for prostate cancer
Date:4/1/2010

Grand Rapids, Mich. (April 1, 2010) Van Andel Research Institute (VARI) scientists have determined how two proteins required for the initiation and development of prostate cancer interact at the molecular level, which could lead to improved treatments for the disease.

One of the proteins, androgen receptor, is already an important drug target for prostate cancer. The other, steroid receptor coactivator-3 (SRC3), was originally identified for its role in the development of breast cancer. SCR3 has also been characterized as a key factor in the development of prostate cancer, but, until now, the exact relationship between androgen receptor and SCR3 has been unclear.

Understanding the relationship between these two proteins, and targeting this interaction, could lead to new, more effective treatments for prostate cancer, the most common form of cancer in men, with more than 192,000 new cases and more than 27,000 deaths reported in the United States in 2009 (Source: National Cancer Institute).

"Anti-androgen therapies become less effective over time," said VARI Distinguished Scientific Investigator H. Eric Xu, Ph.D., whose laboratory published the findings recently in the Journal of Biological Chemistry, where it was named Paper of the Week by the journal. "To develop the next generation of prostate cancer treatments, we need to find ways to disrupt the interaction between androgen receptor and the molecules it depends on to work, such as SRC3."

Androgen receptor activity is required for the initiation and development of prostate cancer. When activated by hormones, androgen receptor binds to DNA in the cell nucleus and regulates gene expression with the help of molecules called coactivators, including SRC3. As a result, genes create more or less of specific proteins in the cell, which can affect cell behavior. Although androgen receptor needs coactivators such as SRC3 to have an effect, little has been known about precisely how androgen receptor interacts with its coactivators.

VARI researchers used peptide profiling and other techniques of molecular biology to discover that SRC3 is a preferred coactivator for androgen receptor. They went on to determine the crystal structures that reveal how androgen receptor and SRC3 interact at the molecular level. This detailed information could be used to develop new, more effective treatments that disrupt interaction between the two proteins.


'/>"/>

Contact: Tim Hawkins
tim.hawkins@vai.org
616-234-5519
Van Andel Research Institute
Source:Eurekalert

Related biology news :

1. LSU researcher receives grant to study equine adult stem cells
2. Grocery shoppers who try harder to track costs do worse, study finds
3. Study uses Chinese wolfberries to improve vision imperfections caused by type-2 diabetes
4. Study shows compulsive eating shares addictive biochemical mechanism with cocaine, heroin abuse
5. Single gene dramatically boosts yield, sweetness in tomato hybrids, CSHL-Israeli study finds
6. Rochester study connects workplace turmoil, stress and obesity
7. Rodeo bull goes head-to-head with zoo dolphins in a study of balance
8. New study may explain how weight-loss surgery reverses type 2 diabetes
9. To close achievement gap, US must address major health risks for urban minority youth, study finds
10. Tectonics: Precision is hallmark of 20-year study
11. Study explores link between sunlight, multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
(Date:2/2/2016)... Va. , Feb. 2, 2016   ... award from the U.S. Army Research Office and ... the range and sensitivity of the company,s ... Past Accounting Mission and, more generally, defense-related DNA ... DNA phenotyping capabilities (predicting appearance and ancestry from ...
(Date:1/28/2016)... 2016 Synaptics (NASDAQ: SYNA ), a leading developer ... quarter ended December 31, 2015. --> ... 2016 increased 2 percent compared to the comparable quarter last year ... 2016 was $35.0 million, or $0.93 per diluted share. ... the first quarter of fiscal 2016 grew 9 percent over the ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal ... its proprietary NeXosome® technology for early warning of ... its most recent study by Dr. Thomas ... the Society for Maternal Fetal Medicine,s (SMFM) annual meeting ... 1-6 th , 2016.  The presentation reported initial ...
(Date:2/10/2016)... 10, 2016  Matchbook, Inc., a company specializing ... biotech companies, announced today the appointment of ... Jim brings nearly 25 years of experience in ... spent nearly two decades in executive level roles ... at Genzyme and, most recently headed global logistics ...
(Date:2/10/2016)... ... February 10, 2016 , ... PatientCrossroads announces that ... secure online PatientCrossroads platform, has exceeded both its one-year and overall recruitment goals ... study, which seeks to advance understanding of the hereditary risks for certain kinds ...
(Date:2/9/2016)... ... February 09, 2016 , ... With a presidential election in ... Care Business Conference will bring together over 500 top healthcare leaders for a night ... transformation. The conference, organized by MBA students of the University of Pennsylvania’s Wharton School, ...
Breaking Biology Technology: